z-logo
open-access-imgOpen Access
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Author(s) -
A. Prat,
T. Pascual,
C. De Angelis,
Claudia María De León Gutiérrez,
A. Llombart-Cussac,
tingjie wang,
J. Cortés,
B. Rexer,
L. Paré,
A. Forero,
Annabell Wolff,
Selena Morales,
B. Adamo,
F. Brasó-Maristany,
María Ignacia Wehbi Vidal,
J. Veeraraghavan,
I. Krop,
P. Galván,
A.C. Pavlick,
B. Bermejo,
M. Izquierdo,
Vanessa Rodrik-Outmezguine,
J.S. Reis-Filho,
S.G. Hilsenbeck,
MARCOS ANTÔNIO GOMES DE OLIVEIRA,
M.V Dieci,
G. Griguolo,
R. Fasani,
P. Nuciforo,
Peter J. Park,
P. Conte,
R. Schiff,
Valentina Guarneri,
C.K. Osborne,
M.F. Rimawi
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ccpq-0s57
Subject(s) - blockade , breast cancer , dual (grammatical number) , trastuzumab , oncology , medicine , cancer research , cancer , biology , receptor , art , literature

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom